Strikingly, both CD44 and CDK12 are well-defined PCa tumor suppressors that, when downregulated, (1) have clinically-relevant implications and (2) based on our findings, would be expected to be a direct consequence of sdRNA-D19b and -A24 overexpression, respectively. The gene discussed is CDK12; the disease is posterior cortical atrophy.